Like! I'll take .53...
INVESTMENT SUMMARY
Prescient has sharpened its focus on lead anti-cancer compound PTX-200 and plans to add a Phase Ib trial in acute myeloid leukaemia (AML) to the ongoing Phase I/II trials in breast and ovarian cancers. It has raised ~A$2m through a share purchase plan and placement, which will fund operations until 2017. We raise our valuation to A$49m (A$0.53/share), with the addition of the AML indication for PTX-200 more than offsetting the deferral of Phase 1b trials for PTX-100.
- Forums
- ASX - By Stock
- PTX
- Ann: Edison Investment Research Initiates Coverage
Ann: Edison Investment Research Initiates Coverage, page-2
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
|
|||||
Last
4.1¢ |
Change
0.002(5.13%) |
Mkt cap ! $32.21M |
Open | High | Low | Value | Volume |
4.1¢ | 4.1¢ | 4.0¢ | $3.952K | 97.80K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 92 | 4.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.1¢ | 66249 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 92 | 0.044 |
1 | 3550 | 0.040 |
7 | 489072 | 0.039 |
13 | 1669182 | 0.038 |
2 | 40513 | 0.037 |
Price($) | Vol. | No. |
---|---|---|
0.041 | 66249 | 1 |
0.042 | 180000 | 2 |
0.043 | 300000 | 2 |
0.044 | 100000 | 1 |
0.045 | 407000 | 3 |
Last trade - 15.54pm 25/06/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |